Soluble suppression of tumourigenicity 2 as a predictor of postoperative hepatic failure.

IF 3.5 3区 医学 Q1 SURGERY
BJS Open Pub Date : 2024-05-08 DOI:10.1093/bjsopen/zrae043
Jing Wu, Shadike Apaer, Xiapukaiti Fulati, Dominique A Vuitton, Yunfei Zhang, Jiangduosi Payiziwula, Nuerzhatijiang Anweier, Tao Li, Kahaer Tuerxun, Tuerganaili Aji, Jinming Zhao, Yingmei Shao, Tuerhongjiang Tuxun, Hao Wen
{"title":"Soluble suppression of tumourigenicity 2 as a predictor of postoperative hepatic failure.","authors":"Jing Wu, Shadike Apaer, Xiapukaiti Fulati, Dominique A Vuitton, Yunfei Zhang, Jiangduosi Payiziwula, Nuerzhatijiang Anweier, Tao Li, Kahaer Tuerxun, Tuerganaili Aji, Jinming Zhao, Yingmei Shao, Tuerhongjiang Tuxun, Hao Wen","doi":"10.1093/bjsopen/zrae043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Posthepatectomy liver failure remains a potentially life-threatening complication after hepatectomy. Soluble suppression of tumourigenicity 2 is an injury-related biomarker. The aim of the study was to assess soluble suppression of tumourigenicity 2 elevation after hepatectomy and whether it can predict posthepatectomy liver failure.</p><p><strong>Methods: </strong>This was a single-centre retrospective study including all patients who underwent a liver resection between 2015 and 2019. Plasma concentrations of soluble suppression of tumourigenicity 2 were measured before surgery and at postoperative days 1, 2, 5 and 7. Posthepatectomy liver failure was defined according to the International Study Group of Liver Surgery and the morbidity rate was graded according to the Clavien-Dindo classification.</p><p><strong>Results: </strong>A total of 173 patients were included (75 underwent major and 98 minor resection); plasma levels of soluble suppression of tumourigenicity 2 increased from 43.42 (range 18.69-119.96) pg/ml to 2622.23 (range 1354.18-4178.27) pg/ml on postoperative day 1 (P < 0.001). Postoperative day 1 soluble suppression of tumourigenicity 2 concentration accurately predicted posthepatectomy liver failure ≥ grade B (area under curve = 0.916, P < 0.001) and its outstanding performance was not affected by underlying disease, liver pathological status and extent of resection. The cut-off value, sensitivity, specificity, positive predictive value and negative predictive value of postoperative day 1 soluble suppression of tumourigenicity 2 in predicting posthepatectomy liver failure ≥ grade B were 3700, 92%, 85%, 64% and 97% respectively. Soluble suppression of tumourigenicity 2high patients more frequently experienced posthepatectomy liver failure ≥ grade B (64.3% (n = 36) versus 2.6% (n = 3)) and Clavien-Dindo IIIa higher morbidity rate (23.2% (n = 13) versus 5.1% (n = 6)) compared with soluble suppression of tumourigenicity 2low patients.</p><p><strong>Conclusions: </strong>Soluble suppression of tumourigenicity 2 may be a reliable predictor of posthepatectomy liver failure ≥ grade B as early as postoperative day 1 for patients undergoing liver resection. Its role in controlling hepatic injury/regeneration needs further investigation. Registration number: ChiCTR-OOC-15007210 (www.chictr.org.cn/).</p>","PeriodicalId":9028,"journal":{"name":"BJS Open","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210312/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJS Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjsopen/zrae043","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Posthepatectomy liver failure remains a potentially life-threatening complication after hepatectomy. Soluble suppression of tumourigenicity 2 is an injury-related biomarker. The aim of the study was to assess soluble suppression of tumourigenicity 2 elevation after hepatectomy and whether it can predict posthepatectomy liver failure.

Methods: This was a single-centre retrospective study including all patients who underwent a liver resection between 2015 and 2019. Plasma concentrations of soluble suppression of tumourigenicity 2 were measured before surgery and at postoperative days 1, 2, 5 and 7. Posthepatectomy liver failure was defined according to the International Study Group of Liver Surgery and the morbidity rate was graded according to the Clavien-Dindo classification.

Results: A total of 173 patients were included (75 underwent major and 98 minor resection); plasma levels of soluble suppression of tumourigenicity 2 increased from 43.42 (range 18.69-119.96) pg/ml to 2622.23 (range 1354.18-4178.27) pg/ml on postoperative day 1 (P < 0.001). Postoperative day 1 soluble suppression of tumourigenicity 2 concentration accurately predicted posthepatectomy liver failure ≥ grade B (area under curve = 0.916, P < 0.001) and its outstanding performance was not affected by underlying disease, liver pathological status and extent of resection. The cut-off value, sensitivity, specificity, positive predictive value and negative predictive value of postoperative day 1 soluble suppression of tumourigenicity 2 in predicting posthepatectomy liver failure ≥ grade B were 3700, 92%, 85%, 64% and 97% respectively. Soluble suppression of tumourigenicity 2high patients more frequently experienced posthepatectomy liver failure ≥ grade B (64.3% (n = 36) versus 2.6% (n = 3)) and Clavien-Dindo IIIa higher morbidity rate (23.2% (n = 13) versus 5.1% (n = 6)) compared with soluble suppression of tumourigenicity 2low patients.

Conclusions: Soluble suppression of tumourigenicity 2 may be a reliable predictor of posthepatectomy liver failure ≥ grade B as early as postoperative day 1 for patients undergoing liver resection. Its role in controlling hepatic injury/regeneration needs further investigation. Registration number: ChiCTR-OOC-15007210 (www.chictr.org.cn/).

可溶性抑制肿瘤生成素 2 是预测术后肝功能衰竭的指标。
背景:肝切除术后肝功能衰竭仍是肝切除术后一种可能危及生命的并发症。可溶性抑制肿瘤生成素 2 是一种与损伤相关的生物标志物。该研究旨在评估肝切除术后可溶性抑制肿瘤生成素2的升高,以及它是否能预测肝切除术后肝衰竭:这是一项单中心回顾性研究,包括2015年至2019年期间接受肝切除术的所有患者。在手术前和术后第1、2、5和7天测量血浆中可溶性抑制肿瘤生成素2的浓度。肝切除术后肝功能衰竭根据国际肝脏外科研究小组进行定义,发病率根据克拉维恩-丁多分类法进行分级:共纳入173例患者(75例接受了大部切除术,98例接受了小部切除术);术后第1天,血浆中可溶性抑制肿瘤生成素2的水平从43.42(范围18.69-119.96)pg/ml升至2622.23(范围1354.18-4178.27)pg/ml(P<0.001)。术后第 1 天的可溶性抑癌基因 2 浓度可准确预测肝切除术后肝功能衰竭≥B 级(曲线下面积 = 0.916,P <0.001),其出色的表现不受基础疾病、肝脏病理状态和切除范围的影响。术后第 1 天可溶性抑瘤因子 2 预测肝切除术后肝功能衰竭≥B 级的临界值、敏感性、特异性、阳性预测值和阴性预测值分别为 3700、92%、85%、64% 和 97%。与可溶性抑制肿瘤性2低患者相比,可溶性抑制肿瘤性2高患者肝切除术后肝功能衰竭≥B级的发生率更高(64.3%(36人)对2.6%(3人)),克拉维恩-丁多IIIa发病率更高(23.2%(13人)对5.1%(6人)):结论:可溶性抑瘤因子2可作为肝切除术后肝功能衰竭的可靠预测指标,预测肝切除术后肝功能衰竭的程度最早可在术后第1天≥B级。它在控制肝损伤/再生方面的作用有待进一步研究。注册编号ChiCTR-OOC-15007210 (www.chictr.org.cn/)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BJS Open
BJS Open SURGERY-
CiteScore
6.00
自引率
3.20%
发文量
144
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信